

**MEDIA RELEASE**

**Novartis Pharmaceuticals UK Ltd (Novartis), the UK's largest commercial clinical trial sponsor<sup>1</sup>, celebrates International Clinical Trials Day**

- *Novartis is the largest commercial clinical trials sponsor in the UK<sup>1</sup>*
- *Novartis funds over 10% of all pharmaceutical industry sponsored trials in the UK<sup>1</sup>*
- *Novartis invests £1 million per week on research and development with 16% of sales being reinvested back into R&D<sup>2</sup>*

**Frimley, May 20, 2016** – Today Novartis Pharmaceuticals UK Ltd (Novartis), the largest commercial sponsor of clinical trials in the UK<sup>1</sup>, celebrates International Clinical Trials Day (ICTD). Novartis in the UK funds over 10% of all pharmaceutical industry sponsored trials<sup>3</sup>, which help many patients get early access to innovative medicines.

ICTD is celebrated around the world to commemorate the day that James Lind started his famous trial on the deadly disease scurvy. Clinical trials have developed a great deal since Lind's discovery, but today ICTD helps us remember his work and provides a focal point to raise awareness of the importance of research to healthcare, and highlights how partnerships between patients and healthcare practitioners are vital to high-quality, relevant research.

Novartis is dedicated to that spirit of partnership and collaboration as stated in our Declaration for Patients<sup>4</sup>: *"We collaborate with others to help address some of the world's greatest health challenges, and we work to find solutions to get the right treatment to the right patient at the right time as quickly as possible."*

Novartis plays a valuable role in putting patients in early touch with our innovative treatments. Our clinical trials programme also demonstrates our investment in the UK's science and research base. Globally, Novartis invested \$9.9 billion in research in 2014<sup>5</sup>, and in the UK Novartis invests £1 million per week on research and development with 16% of sales being reinvested back into R&D<sup>2</sup>.

"It is vital for patients that we maintain strong partnerships with the UK's world leading scientific and research communities, and ensure that the UK becomes a first choice for clinical trials globally," explains Dimitrios Georgiopoulos, MD, UK Chief Scientific Officer.

"We are proud of the contribution our clinical trials programme makes to improving the lives of patients throughout the UK, and we are committed to continuing to grow our trials programme in the UK in the future."

For more than 15 years, Novartis has supported data transparency and was one of the first to publish trial results of innovative medicines within one year of study completion, regardless of outcome. Novartis recognises the importance of informing the public about the results of its clinical trials for innovative compounds, regardless of the outcome. Novartis make the results of its clinical trials publicly available through peer-reviewed

publications and posting of results on the Novartis clinical trial results database and other online public databases.

### **About Novartis**

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 120,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit [www.novartis.co.uk](http://www.novartis.co.uk).

# # #

### **Novartis Media contacts**

Novartis Pharmaceuticals UK Ltd  
Email: [press.office@novartis.com](mailto:press.office@novartis.com)  
Tel: +44 7920 467679 (Press Office)

---

#### References:

- <sup>1</sup> Novartis Pharmaceuticals UK Ltd. (2015) *Partnerships for better patient outcomes*. [Brochure]. Novartis, Frimley. <https://www.novartis.co.uk/> Accessed 17th May 2016
- <sup>2</sup> <https://www.novartis.co.uk/our-work/rd-uk> Accessed 17th Mar 2016
- <sup>3</sup> Novartis Pharmaceuticals UK Ltd. (2015) *Partnerships for better patient outcomes*. [Brochure]. Novartis, Frimley. <https://www.novartis.co.uk/> Accessed 17th May 2016
- <sup>4</sup> <https://www.novartis.co.uk/about-us/who-we-are/our-mission> Accessed 17th May 2016
- <sup>5</sup> Novartis Pharmaceuticals UK Ltd. (2015) *Partnerships for better patient outcomes*. [Brochure]. Novartis, Frimley. <https://www.novartis.co.uk/> Accessed 17th May 2016